BioSpace News Archive

Amphivena Therapeutics, a clinical-stage oncology company focused on developing immunotherapeutics that restore anti-cancer immunity in patients, presented data on a novel assay for selection of acute myeloid leukemia patients for treatment with AMV564, at the 62nd Annual American Society of Hematology Meeting and Exposition, taking place virtually from December 5-8, 2020.

67% spleen volume response rate observed in 63 first-line myelofibrosis patients treated with CPI-0610 + ruxolitinib at 24 weeks

PD-L1 positive subjects demonstrated Objective Response Rate (ORR) of 86 % associated with long duration of clinical benefits

MRD assessment with clonoSEQ improves outcomes both for patients and the healthcare system, as patients with undetectable MRD may be able to discontinue active treatment

Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, announced the presentation of new preclinical data on AO-176 at the ASH Annual Meeting 2020.

Investigational New Drug (IND) Application for ALLO-316 Cleared by U.S. Food and Drug Administration (FDA); Phase 1 Trial in RCC to Start in 2021

Data demonstrate potential to differentiate between the two major forms of amyloidosis - ATTR and AL - and non invasive detection of systemic AL amyloidosis in multiple organ systems

Early multi-center results indicate that Orca-T, a novel approach to HSCT,improves time-to-engraftment, markedly reducesthe incidence and severity of GvHD, and significantly improved GRFS at 1 year

Kadmon Holdings, Inc. announced 12-month data from ROCKstar, its ongoing pivotal trial of belumosudil for the treatment of patients with chronic graft-versus-host disease, in an oral session at the 62nd American Society of Hematology Annual Meeting.

IMBRUVICA® pooled clinical trial analyses presented at ASH demonstrate sustained efficacy and safety in patients with historically poor outcomes